Pharmacogenetic tests in psychiatry

Journal of Clinical Psychopharmacology

Volumn 36, Issue 4, 2016, Pages 299-304

  De Leon, Jose ^a,b,c  

^a Eastern State Hospital   (United States)

^b UNIVERSITY OF GRANADA   (Spain)

^c UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; RISPERIDONE; TRICYCLIC ANTIDEPRESSANT AGENT;

DNA MICROARRAY; FLUOROSCOPY; GENETIC SCREENING; HUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; PSYCHIATRIC TREATMENT; PSYCHIATRIST; PSYCHIATRY; REVIEW; GENETICS; MENTAL DISORDERS; PROCEDURES;

HUMANS; MENTAL DISORDERS; PHARMACOGENETICS; PSYCHIATRY;

EID: 84973299592     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000522     Document Type: Review

References (60)

1. Shader RI. Some thoughts about medical caring. J Clin Psychopharmacol. 2015; 35: 115-116.
2. de Leon J. Evidence-based medicine versus personalized medicine: are they enemies?. J Clin Psychopharmacol. 2012; 32: 153-164.
3. Fodor SP. Massively parallel genomics. Science. 1997; 277: 393-395.
4. Chaudhuri JD. Genes arrayed out for you: the amazing world of microarrays. Med Sci Monit. 2005; 11: RA52-RA62.
5. Science. New research horizons. Science. 1997; 278: 2039.
6. Vahey M, Nau ME, Barrick S, et al. Performance of the Affymetrix GeneChip HIV PRT 440 platform for antiretroviral drug resistance genotyping of human immunodeficiency virus type 1 clades and viral isolates with length polymorphisms. J ClinMicrobiol. 1999; 37: 2533-2537.
7. Simpson GM, Josiassen RC, Stanilla JK, et al. Double-blind study of clozapine dose response in chronic schizophrenia. Am J Psychiatry. 1999; 156: 1744-1750.
8. Bertilsson L, Carrillo JA, Dahl ML, et al. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol. 1994; 38: 471-473.
9. Odom-White A, de Leon J. Clozapine levels and caffeine. J Clin Psychiatry. 1996; 57: 175-176.
10. Chen S, Chou WH, Blouin RA, et al. The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. Clin Pharmacol Ther. 1996; 60: 522-534.
11. de Leon J, Barnhill J, Rogers T, et al. Pilot study of the cytochrome P450-2D6 genotype in a psychiatric state hospital. Am J Psychiatry. 1998; 155: 1278-1280.
12. Huang ML, Van Peer A, Woestenborghs R, et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther. 1993; 54: 257-268.
13. Bork JA, Rogers T, Wedlund PJ, et al. A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A. J Clin Psychiatry. 1999; 60: 469-476.
14. Chou WH, Yan FX, de Leon J, et al. Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. J Clin Psychopharmacol. 2000; 20: 246-251.
15. de Leon J, Susce MT, Pan RM, et al. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry. 2005; 66: 15-27.
16. de Leon J, Susce MT, Pan RM, et al. A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels. Pharmacopsychiatry. 2007; 40: 93-102.
17. Shah RR, Smith RL. Addressing phenoconversion: the Achilles' heel of personalized medicine. Br J Clin Pharmacol. 2015; 79: 222-240.
18. de Leon J. Phenoconversion and therapeutic drug monitoring. Br J Clin Pharmacol. 2015; 80: 777-778.
19. Cappell K, ArndtM, Carey J. Drugs get smart. BusinessWeek. 2005: 76-85.
20. Wagner JA. Overview of biomarkers and surrogate endpoints in drug development. Dis Markers. 2002; 18: 41-46.
21. de Leon J. Is psychiatry only neurology?. Or only abnormal psychology?. Déjà vu after 100 years. Acta Neuropsychiatr. 2015; 27: 69-81.
22. de Leon J. One hundred years of limited impact of Jaspers' General Psychopathology on US psychiatry. J NervMent Dis. 2014; 202: 79-87.
23. de Leon J, Susce MT, Murray-Carmichael E. The AmpliChip CYP450 genotyping test: integrating a new clinical tool. Mol Diagn Ther. 2006; 10: 135-151.
24. SadeeW. Pharmacogenomics: the implementation phase. AAPS PharmSci. 2002; 4: E5.
25. Weinshilboum R, Wang L. Pharmacogenomics: bench to bedside. Nat Rev Drug Discov. 2004; 3: 739-748.
26. de Leon J. Pharmacogenomics: the promise of personalized medicine for CNS disorders. Neuropsychopharmacology. 2009; 34: 159-172.
27. de Leon J. AmpliChip CYP450 test: personalized medicine has arrived in psychiatry. Expert Rev Mol Diagn. 2006; 6: 277-286.
28. de Leon J, Arranz MJ, Ruaño G. Pharmacogenetic testing in psychiatry: a review of features and clinical realities. Clin Lab Med. 2008; 28: 599-617.
29. Melis R, Lyon E, McMillin GA. Determination of CYP2D6, CYP2C9 and CYP2C19 genotypes with Tag-It mutation detection assays. Expert Rev Mol Diagn. 2006; 6: 811-820.
30. Ruaño G, Kocherla M, Graydon JS, et al. Practical interpretation of CYP2D6 haplotypes: comparison and integration of automated and expert calling. Clin Chim Acta. 2016; 456: 7-14.
31. Drozda K, Müller DJ, Bishop JR. Pharmacogenomic testing for neuropsychiatric drugs: current status of drug labeling, guidelines for using genetic information and test options. Pharmacotherapy. 2014; 34: 166-184.
32. Crettol S, de Leon J, Hiemke C, et al. Pharmacogenomics in psychiatry: from therapeutic drug monitoring to genomic medicine. Clin Pharmacol Ther. 2014; 95: 254-257.
33. Sim SC, Risinger C, Dahl ML, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther. 2006; 79: 103-113.
34. de Leon J, Susce MT, Johnson M, et al. DNA microarray technology in the clinical environment: the AmpliChip CYP450 test for CYP2D6 and CYP2C19 genotyping. CNS Spectr. 2009; 14: 19-34.
35. Shah RR. Pharmacogenetics in drug regulation: promise, potential and pitfalls. Philos Trans R Soc Lond B Biol Sci. 2005; 360: 1617-1638.
36. The Secretary's Advisory Committee on Genetics, Health and Society (SACGHS). Coverage and Reimbursement of Genetic Tests and Services February 2006. Available at: http://osp.od.nih.gov/office-clinical-researchand-bioethics-policy/genetics-health-And-society/sacghs-Archives/.documents. Accessed May 21, 2016.
37. de Leon J, Spina E.What is needed to incorporate clinical pharmacogenetic tests into the practice of psychopharmacotherapy?. Expert Rev Clin Pharmacol. 2016; 9: 351-354.
38. de Leon J. Focusing on drug versus disease mechanisms and on clinical subgrouping to advance personalised medicine in psychiatry. Acta Neuropsychiatr. 2014; 26: 327-333.
39. Karlović D, Karlović D. Serotonin transporter gene (5-HTTLPR) polymorphism and efficacy of selective serotonin reuptake inhibitors-do we have sufficient evidence for clinical practice. Acta Clin Croat. 2013; 52: 353-362.
40. Porcelli S, Fabbri C, Serretti A.Meta-Analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur Neuropsychopharmacol. 2012 22 239-258.
41. Lipsky RH, Hu XZ, Goldman D. Additional functional variation at the SLC6A4 gene. Am J Med Genet B Neuropsychiatr Genet. 2009; 150B: 153.
42. Parsey RV, Hastings RS, Oquendo MA, et al. Effect of a triallelic functional polymorphism of the serotonin-Transporter-linked promoter region on expression of serotonin transporter in the human brain. Am J Psychiatry. 2006; 163: 48-51.
43. Reynolds GP, McGowan OO, Dalton CF. Pharmacogenomics in psychiatry: the relevance of receptor and transporter polymorphisms. Br J Clin Pharmacol. 2014; 77: 654-672.
44. Swen JJ, Nijenhuis M, de Boer A, et al. Pharmacogenetics: from bench to byte-An update of guidelines. Clin Pharmacol Ther. 2011; 89: 662-673.
45. Hicks JK, Swen JJ, Thorn CF, et al. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther. 2013; 93: 402-408.
46. Hicks JK, Bishop JR, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther. 2015; 98: 127-134.
47. Rogers HL, Bhattaram A, Zineh I, et al. CYP2D6 genotype information to guide pimozide treatment in adult and pediatric patients: basis for the U.S. Food and Drug Administration's new dosing recommendations. J Clin Psychiatry. 2012; 73: 1187-1190.
48. Jaquenoud Sirot E, Knezevic B, Morena GP, et al. ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine. J Clin Psychopharmacol. 2009; 29: 319-326.
49. Preskorn SH, Kane CP, Lobello K, et al. Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine. J Clin Psychiatry. 2013; 74: 614-621.
50. de Leon J. Translating pharmacogenetics to clinical practice: do cytochrome P450 2D6 ultrarapid metabolizers need higher atomoxetine doses?. J Am Acad Child Adolesc Psychiatry. 2015; 54: 532-534.
51. Spina E, de Leon J. Clinical applications of CYP genotyping in psychiatry. J Neural Transm (Vienna). 2015; 122: 5-28.
52. Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004; 428: 486.
53. Chen P, Lin JJ, Lu CS, et al. Carbamazepine-induced toxic effects and HLA-B 1502 screening in Taiwan. N Engl J Med. 2011; 364: 1126-1133.
54. Jones PM. FDA regulation of LDTs-An update. MLO Med Lab Obs. 2015; 47: 18-19.
55. Spina E, Pisani F, de Leon J. Clinically significant pharmacokinetic drug interactions of antiepileptics drugs with new antidepressants and new antipsychotics. Pharmacol Res. 2016; 106: 72-86.
56. de Leon J. Paradoxes of US psychopharmacology practice in 2013: undertreatment of severe mental illness and overtreatment of minor psychiatric problems. J Clin Psychopharmacol. 2014; 34: 545-548.
57. Pies RW. Antidepressants: conundrums and complexities of efficacy studies. J Clin Psychopharmacol. 2016; 36: 1-4.
58. Ebrahim S, Bance S, Athale A, et al. Meta-Analyses with industry involvement are massively published and report no caveats for antidepressants. J Clin Epidemiol. 2016; 70: 155-163.
59. Fibiger HC. Psychiatry, the pharmaceutical industry, and the road to better therapeutics. Schizophr Bull. 2012; 38: 649-650.
60. Klein DF, Glick ID, Shader RI. Central nervous system drug development, basic, and clinical research thinking outside the box. J Clin Psychopharmacol. 2011; 31: 553-554.